Abstract:

Programmed cell death-1 (PD-1) / programmed cell death-ligand 1 (PD-L1) are important immune checkpoints, which play pivotal roles in suppressing anti-cancer immunity and are involved in immune escape mechanism of tumor cells. PD-1/PD-L1 inhibitors have achieved remarkable therapeutic effects in non-small-cell lung cancer, advanced melanoma, thyroid carcinoma, and other tumors by blocking the binding of PD-1 on activated T-cells to PD-L1 expressed on tumor cells. This paper mainly reviews the progress in PD-1 inhibitors in the treatment of thyroid carcinoma.

Key words:

Thyroid carcinoma, Immune checkpoint inhibitors, Programmed cell death-1, Molecular targeted therapy, Progress

摘要：

程序性死亡受体1（programmed cell death 1，PD-1）/程序性死亡配体1（programmed cell death-ligand 1，PD-L1）是重要的免疫检查点，在抑制抗肿瘤免疫反应中起作用，参与肿瘤细胞免疫逃逸机制。PD-1/PD-L1抑制剂通过阻断活化的T细胞上的PD-1与表达PD-L1的肿瘤细胞结合，在非小细胞肺癌、晚期黑色素瘤、甲状腺癌等多种肿瘤治疗中取得了良好的治疗效果。本文主要对PD-1抑制剂在甲状腺癌治疗中的研究进展进行综述。

关键词:

甲状腺癌, 免疫检查点抑制剂, 程序性死亡受体1, 分子靶向治疗, 进展